Corrigendum to 'The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine' [European Journal of Cancer 44 (2008) 2615-2622] (DOI:10.1016/j.ejca.2008.08.010);The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine

European Journal of Cancer

Volumn 44, Issue 17, 2008, Pages 2615-2622

  Lopatriello, S ^a   Amoroso, D ^b   Donati, S ^b   Alabiso, O ^c   Forti, L ^c   Fornasiero, A ^d   Smergo, A ^d   Lalli, A ^e   Iacono, C ^f   Lucenti, A ^f   D'Alonzo, L ^g   Negrini, C ^a  

^a Pbe Consulting   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c Azienda Ospedaliera Universitaria Maggiore Della Carita   (Italy)

^d Ospedale Immacolata Concezione   (Italy)

^e Medical Oncology Unit   (Italy)

^f Azienda Ospedaliera Civile Maria Paterno Arezzo   (Italy)

^g CM Pharma   (Italy)

Author keywords

CRC; Direct medical costs; Infusional oral administration routes

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVOFOLINATE; OXALIPLATIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG COST; DRUG INFUSION; FEMALE; GRANULOMA; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH STATUS; HOSPITAL; HOSPITAL COST; HUMAN; INTESTINE OBSTRUCTION; ITALY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SKIN INFECTION; THROMBOCYTOPENIA;

EID: 55549107476     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.028     Document Type: Erratum

References (28)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 3 (2007) 581-592
2. Rosso S., Spitale A., Balzi D., Franceschi S., and Zanetti R. Estimate of cancer incidence in Italian regions, 2001. Epidemiol Prev 28 4-5 (2004) 247-257
3. Zanetti R., Falcini F., Simonato L., and Vercelli M. Survival of cancer patients in Italy in the nineties: the importance of population based data. Epidemiol Prev 25 3 Suppl (2001) 1-8
4. AIOM. Linee guida AIOM 2007. Tumori del Colon-Retto. 2007.
5. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-914
6. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
7. Schmoll H.J., and Arnold D. Update on capecitabine in colorectal cancer. Oncologist 11 9 (2006) 1003-1009
8. Feliu J., Escudero P., Llosa F., et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 23 13 (2005) 3104-3111
9. Cavallo MC, Gerzeli S, De Carli C, Nobile MT, Gallo Stampino C. The cost of treatment of advanced colorectal cancer: a restrospective comparison of five chemotherapy regimens used in Northen Italy hospital. 3rd ed., 2001, 49-59.
10. Pasetto L.M., Jirillo A., Iadicicco G., Rossi E., Paris M.K., and Monfardini S. FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 25 1 (2005) 563-576
11. Drummond M.F., O'Brien B., Stoddard G.L., and Torrance G.W. Cost analysis. Methods for the economic evaluation of health care programmes. 2nd ed. (1997), Oxford University Press 52-95
12. AIFA. Prontuario Farmaceutico Nazionale. http://www.agenziafarmaco.it/section8983.html 2007 February 9.
13. Ministero della Salute. Tempi Medi di Attività, Modalità di Esecuzione. Nomenclatore delle Prestazioni Specialistiche Ambulatoriali Territoriali. 2006.
14. Ministero della Salute. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera. Decreto Ministeriale. 2006.
15. Verona University Hospital. Hospital Formulary List. 2007.
16. Biffi R., dedfdsfsd B.F., Orsi F., et al. Totally implantable central venous access ports for long-term chemotherapy A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol l9 7 (1998) 767-773
17. Schivazappa C., Baldini E., Cortesi E., Dauria G., Roila F., and Berto P. Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study. Recenti Prog Med 98 1 (2007) 12-15
18. Regione del Veneto. Prestazioni di chemioterapia e radioterapia. BUR n. 734, 20/03/2007 ed. 2007.
19. Regione Piemonte. Tariffe DRG istituti pubblici. 01/01/2006 ed. 2006.
20. Borner M., Scheithauer W., Twelves C., Maroun J., and Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 6 Suppl 4 (2001) 12-16
21. Giuliani G, Lucioni C, Mazzi S, De Carli C, Jamieson C. Valutazione di convenienza economica comparata tra un farmaco orale (capecitabina) e una terapia parenterale a base di 5-FU (regime Mayo) nel trattamento del carcinoma del colon-retto metastizzato). 4th ed., 2002, 13-38.
22. Limat S., Bracco-Nolin C.H., Legat-Fagnoni C., et al. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. Eur J Health Econ 7 2 (2006) 107-113
23. Ward S., Kaltenthaler E., Cowan J., and Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 7 32 (2003) 1-93
24. Mayer R.J. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?. J Clin Oncol 25 27 (2007) 4165-4167
25. Loupakis F., Masi G., Vasile E., and Falcone A. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. Curr Opin Oncol 20 4 (2008) 459-465
26. Liu G., Franssen E., Fitch M.I., and Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15 1 (1997) 110-115
27. Pfeiffer P., Mortensen J.P., Bjerregaard B., et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 42 16 (2006) 2738-2743
28. Catania C., Didier F., Leon M.E., et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 92 3 (2005) 265-272